Top Markets
#1 Black Phoenix Black Phoenix +21,324.94%
#2 Nesa Nesa +680.44%
#3 Ontology Gas Ontology Gas +77.37%
#4 Kinesis Silver Kinesis Silver +53.96%
#5 Biconomy Biconomy +30.85%
#6 QuantixAI QuantixAI +23.11%
#7 EXOD EXOD +22.78%
#8 SAFEcoin SAFEcoin +19.07%
#9 BNB Attestation Service BNB Attestation Service +18.39%
#10 Magma Finance Magma Finance +17.20%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Medigen Biotechnology Corp. Medigen Biotechnology Corp.

Medigen Biotechnology Corp.

3176
Clasificación en acciones #19057
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Precio por acción
$1.27
Capitalización bursátil
$176.31M
Cambio (1 día)
5.57%
Cambio (1 año)
29.36%
País
TW
Comercio Medigen Biotechnology Corp. (3176)

Categoría

Healthcare
Ingresos de Medigen Biotechnology Corp. (3176)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Medigen Biotechnology Corp., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Medigen Biotechnology Corp. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH